CAMPATH-IH in multiple sclerosis.

Journal article

In a pilot study, seven patients with multiple sclerosis were treated with CAMPATH-IH which targets the CD52 antigen present on lymphocytes and monocytes. There was a substantial reduction in disease activity as measured by gadoliunium-enhancing lesions on MRI. Encouraged by this result a further seven patients have been treated with CAMPATH-IH; four also received anti-CD4 antibody. Lymphopaenia developed rapidly and was sustained for at least one year. In 12 patients, the first infusion of a...

Expand abstract

Authors: Moreau, T; Coles, A; Wing, M; Thorpe, J; Miller, D

• Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
• Volume: 1
• Issue: 6
• Pages: 357-365
• Publication date: 1996-07-01
• EISSN: 1477-0970
• ISSN: 1352-4585
• Language: English
• Keywords: Cell Count; Antibodies, Monoclonal; Magnetic Resonance Imaging; Multiple Sclerosis; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Neural Conduction; Pilot Projects; Adrenal Cortex Hormones; Humans; Cytokines